ASX Share rice
Thu 13 May 2021 - 01:12:pm (Sydney)

EX1 Share Price

EXOPHARM LIMITEDEX1Pharmaceuticals, Biotechnology & Life Sciences

EX1 Company Information

Name:

Exopharm Limited

Sector:

Healthcare

Industry:

Biotechnology

Address:

31 Queen Street Melbourne VIC Australia 3000

Phone:

61 3 9111 0026

Full Time Employees:

41

Company Founder, Technology Co-Founder, MD & Director:

Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.

Chief Operating Officer:

Dr. Gregor Lichtfuss M.Sc.

Chief Commercial Officer:

Dr. Christopher Baldwin Ph.D.

Company Sec. & Non-Exec. Director:

Ms. Elizabeth McGregor B.A., M.B.A.

Company Overview:

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Naïve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.

EX1 Share Price Information

Shares Issued:

156.08M

Market Capitalisation:

$93.65M

Revenue (TTM):

$2.72M

Revenue Per Share (TTM):

$0.03

Earnings per Share:

$-0.04

Profit Margin:

-2.7396

Operating Margin (TTM):

$-2.75

Return On Assets (TTM):

$-0.49

Return On Equity (TTM):

$-0.92

Quarterly Revenue Growth (YOY):

-0.328

Gross Profit(TTM):

$-314,976

Diluted Earnings Per Share (TTM):

$-0.07

EX1 CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-949,593

Change To Liabilities:

$331.25K

Total Cashflow From Investing Activities:

$-949,593

Net Borrowings:

$-184,846

Net Income:

$-5,278,803

Total Cash From Operating Activities:

$-6,696,656

Depreciation:

$382.42K

Other Cashflow From Investing Activities:

$-317,791

Sale Purchase Of Stock:

$5.18M

Capital Expenditures:

$631.80K

EX1 Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-5,278,800

Net Income:

$-5,278,800

Gross Profit:

$2.62M

Operating Income:

$-5,278,810

Total Revenue:

$2.73M

EX1 Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$325K

Total Liabilities:

$1.53M

Total Stockholder Equity:

$5.02M

Other Current Liabilities:

$238.10K

Total Assets:

$6.54M

Common Stock:

$12.76M

Other Current Assets:

$20.03K

Retained Earnings:

$-7,738,301

Other Assets:

$317.79K

Cash:

$1.74M

Total Current Liabilities:

$0.92M

Property - Plant & Equipment:

$1.84M

Net Tangible Assets:

$4.69M

Long-Term Investments:

$277.79K

Total Current Assets:

$4.06M

Net Receivables:

$2.18M

Short-Term Investments:

$2.48M

Accounts Payable:

$137.62K

Non Currrent Assets (Other):

$40K

Short-Term Investments:

$2.48

Non Current Liabilities Total:

$603.74K

EX1 Share Price History

EX1 News

10 May, 2021
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
20 Feb, 2021
Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...
25 Aug, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...